Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 161 clinical trials
A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

This study is a multicenter, open-label, multi-cohort phase II clinical trials to evaluate the efficacy and safety of TQB3616 capsules combined with Fulvestrant injection in subjects with HR-positive and HER2-negative advanced and/or metastatic breast cancer, including Cohort 1 and Cohort 2. Each cohort will enroll 30-60 cases.

  • 0 views
  • 04 Mar, 2021
  • 20 locations
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+ HER2- Advanced Breast Cancer Patients (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their

metastasis
measurable disease
progesterone receptor
cish
her2-negative breast cancer
  • 0 views
  • 27 Jan, 2021
  • 49 locations
Olaparib+Trastuzumab in HER2[+] Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer

advanced breast cancer

metastasis
ovarian suppression
liver metastasis
measurable disease
olaparib
  • 6 views
  • 27 Jan, 2021
  • 27 locations
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer

This is a multicenter single-arm phase II clinical trial to evaluate the efficacy and safety of olaparib in patients diagnosed of advanced triple negative breast cancer (TNBC) with methylation of BRCA1 and/or BRCA2 promoters assessed in DNA from metastatic lesions and absence of BRCA1 and 2 germline mutations.

estrogen receptor
progesterone receptor
etonogestrel
MRI
blood transfusion
  • 18 views
  • 29 Jan, 2021
  • 25 locations
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

This is a monocentric cohort study, prospective and interventional with minimal risks and constraints for advanced breast cancer. The planned interventions are collection of biological samples

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

This is a phase IB/II clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole or Fulvestrant. Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for study.

metastasis
measurable disease
fulvestrant
cancer therapy
endocrine therapy
  • 34 views
  • 23 Jan, 2021
  • 4 locations
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer

The purpose of this randomized phase III trial is to evaluate the clinical benefit of combining entinostat with exemestane in Chinese patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer, who have disease progression on endocrine therapy. Additionallythe safety, tolerability, and PK profile of the treatment combination are evaluated.

denosumab
estrogen receptor
progesterone receptor
hormone therapy
progesterone
  • 8 views
  • 23 Jan, 2021
  • 1 location
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole versus placebo in combination with Letrozole or Anastrozole in Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible …

cancer therapy
anastrozole
HER2
stage iv breast cancer
  • 0 views
  • 25 Jan, 2021
A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

(MTD) of monotherapy. 2.To evaluate the safety and tolerability of LXI-15029 in Chinese postmenopausal patients with metastatic or locally advanced breast cancer with estrogen receptor (+) and human

lxi-15029
human epidermal growth factor
measurable disease
estrogen receptor
tumor cells
  • 18 views
  • 26 Jan, 2021
  • 1 location
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

(HER2)-negative, advanced breast cancer harboring a PIK3CA mutation in Japan, whose disease has progressed on or after aromatase inhibitor (AI) treatment regardless of prior CDK4/6 inhibitor use.

PIK3CA
human epidermal growth factor
measurable disease
fulvestrant
cish
  • 0 views
  • 04 Mar, 2021
  • 7 locations